Shailesh Advani1,2, Dongyu Zhang3, Martin Tammemagi4, Tomi Akinyemiju5, Michael K Gould6, Gerard A Silvestri7, Dejana Braithwaite3. 1. Department of Oncology, Georgetown University School of Medicine, Georgetown University, Washington, DC. 2. Transplant Research Education Center, Terasaki Institute of Biomedical Innovation, Los Angeles, California. 3. University of Florida Health Cancer Center, Department of Epidemiology, and Department of Aging and Geriatric Research, University of Florida, Gainesville, Florida. 4. Department of Health Sciences, Brock University, St. Catherines, Ontario, Canada. 5. Department of Population Health Sciences, Duke University School of Medicine, Durham, North Carolina. 6. Department of Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, California; and. 7. Division of Pulmonary and Critical Care Medicine, Medical University of South Carolina, Charleston, South Carolina.
Abstract
Rationale: Although lung cancer screening (LCS) with low-dose computed tomography (LDCT) is now recommended for those meeting standard risk factor-based eligibility criteria, the role of comorbidity in the uptake of LCS with LDCT in an older real-world U.S. population is not well established. Objectives: To examine the relationships between comorbidity, functional status, and LCS utilization in the United States. Methods: Using population-based data from the 2017-2019 Behavioral Risk Factor Surveillance System, we examined the association of comorbid conditions and functional limitations regarding activities of daily living with LCS utilization among participants that met the LCS criteria based on the U.S. Preventive Service Taskforce guidelines. We employed multivariable weighted logistic regression models to evaluate these associations, both overall and within subgroups defined by age (<65 yr vs. ⩾65 yr), sex, and smoking history. Results: Of 11,214 participants who met the eligibility criteria for LCS, 1,731 (16%) underwent LCS with LDCT. The majority were White (90%), male (55%), former smokers (52%), and living with at least one chronic comorbid condition (77%). More than 28% had three or more comorbid conditions, and approximately 40% of participants reported having some form of functional limitations. In the multivariable models, the likelihood of undergoing LCS with LDCT within the past year was positively associated with higher amount of comorbidity (⩾5 vs. 0: adjusted odds ratio, 2.34; 95% confidence interval [CI], 1.22-4.48) but not with functional limitations (⩾3 vs. 0: adjusted odds ratio, 1.00; 95% CI, 0.66-1.50). Conclusions: The presence of comorbid conditions is associated with a higher likelihood of undergoing LCS with LDCT. Because poor health status may diminish the benefits of screening, future research is needed to precisely characterize the health status of LCS-eligible individuals.
Rationale: Although lung cancer screening (LCS) with low-dose computed tomography (LDCT) is now recommended for those meeting standard risk factor-based eligibility criteria, the role of comorbidity in the uptake of LCS with LDCT in an older real-world U.S. population is not well established. Objectives: To examine the relationships between comorbidity, functional status, and LCS utilization in the United States. Methods: Using population-based data from the 2017-2019 Behavioral Risk Factor Surveillance System, we examined the association of comorbid conditions and functional limitations regarding activities of daily living with LCS utilization among participants that met the LCS criteria based on the U.S. Preventive Service Taskforce guidelines. We employed multivariable weighted logistic regression models to evaluate these associations, both overall and within subgroups defined by age (<65 yr vs. ⩾65 yr), sex, and smoking history. Results: Of 11,214 participants who met the eligibility criteria for LCS, 1,731 (16%) underwent LCS with LDCT. The majority were White (90%), male (55%), former smokers (52%), and living with at least one chronic comorbid condition (77%). More than 28% had three or more comorbid conditions, and approximately 40% of participants reported having some form of functional limitations. In the multivariable models, the likelihood of undergoing LCS with LDCT within the past year was positively associated with higher amount of comorbidity (⩾5 vs. 0: adjusted odds ratio, 2.34; 95% confidence interval [CI], 1.22-4.48) but not with functional limitations (⩾3 vs. 0: adjusted odds ratio, 1.00; 95% CI, 0.66-1.50). Conclusions: The presence of comorbid conditions is associated with a higher likelihood of undergoing LCS with LDCT. Because poor health status may diminish the benefits of screening, future research is needed to precisely characterize the health status of LCS-eligible individuals.
Authors: Lynn T Tanoue; Nichole T Tanner; Michael K Gould; Gerard A Silvestri Journal: Am J Respir Crit Care Med Date: 2015-01-01 Impact factor: 21.405
Authors: Juan P de-Torres; Jose M Marín; Ciro Casanova; Victor Pinto-Plata; Miguel Divo; Claudia Cote; Bartolome R Celli; Javier J Zulueta Journal: Chest Date: 2016-01-12 Impact factor: 9.410
Authors: Denise R Aberle; Amanda M Adams; Christine D Berg; William C Black; Jonathan D Clapp; Richard M Fagerstrom; Ilana F Gareen; Constantine Gatsonis; Pamela M Marcus; JoRean D Sicks Journal: N Engl J Med Date: 2011-06-29 Impact factor: 91.245
Authors: Anil K Chaturvedi; Hormuzd A Katki; Stephanie A Kovalchik; Martin Tammemagi; Christine D Berg; Neil E Caporaso; Tom L Riley; Mary Korch; Gerard A Silvestri Journal: N Engl J Med Date: 2013-07-18 Impact factor: 91.245
Authors: Louise C Walter; Karla Lindquist; Sean Nugent; Tammy Schult; Sei J Lee; Michele A Casadei; Melissa R Partin Journal: Ann Intern Med Date: 2009-04-07 Impact factor: 25.391
Authors: Paul F Pinsky; David S Gierada; William Hocking; Edward F Patz; Barnett S Kramer Journal: Ann Intern Med Date: 2014-11-04 Impact factor: 25.391
Authors: Randi M Williams; Tengfei Li; George Luta; Min Qi Wang; Lucile Adams-Campbell; Rafael Meza; Martin C Tammemägi; Kathryn L Taylor Journal: Cancer Date: 2022-02-24 Impact factor: 6.860
Authors: Dejana Braithwaite; Shama D Karanth; Christopher G Slatore; Dongyu Zhang; Jiang Bian; Rafael Meza; Jihyoun Jeon; Martin Tammemagi; Mattthew Schabath; Meghann Wheeler; Yi Guo; Bruno Hochhegger; Frederic J Kaye; Gerard A Silvestri; Michael K Gould Journal: BMJ Open Date: 2022-06-22 Impact factor: 3.006
Authors: Eman M Metwally; M Patricia Rivera; Danielle D Durham; Lindsay Lane; Pasangi Perera; Derek Lamb; Louise M Henderson Journal: JAMA Netw Open Date: 2022-09-01